CiNPWT Lower Extremity Amputations (Closed Incision Neagtive Pressure Wound Therapy)
NCT ID: NCT06493539
Last Updated: 2026-01-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE1
Study Classification
INTERVENTIONAL
Study Start Date
2024-07-25
Study Completion Date
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this study is to evaluate prospectively the effect of a novel application of Closed Incision Negative Pressure Wound Therapy(CiNPWT), as delivered by the V.A.C. Ulta™ Therapy System (3M, USA) in individuals who have undergone a Lower Extremity Amputation(LEA) compared with standard of care compression wrapping and wound care post-LEA.
This a pilot-controlled exploratory trial including approximately 6-10 individuals who have undergone LEA (trans-metatarsal or higher) randomized between intervention (novel application of CiNPWT) and a control group (standard care).
This a pilot-controlled exploratory trial including approximately 6-10 individuals who have undergone LEA (trans-metatarsal or higher) randomized between intervention (novel application of CiNPWT) and a control group (standard care).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Outcomes for Incisional Application of Negative Pressure for Nontraumatic Amputations
NCT03250442
Surgical Wound
Wound Heal
Amputation
UNKNOWN
NA
Negative Pressure Wound Therapy for Surgical Wounds of the Foot and Ankle
NCT02739191
Negative Pressure Wound Therapy
Vacuum Therapy
Closed Incisions
COMPLETED
NA
Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications
NCT03773575
Amputation
Amputation; Postoperative, Sequelae
Wound Dehiscence
+3 more
COMPLETED
NA
Assessing the Feasibility of a Virtual Reality Intervention for Phantom Pain Immediately Following Lower Limb Amputation
NCT06638918
Phantom Limb Pain
COMPLETED
Total Contact Soft Cast in Diabetic Foot Ulcers
NCT04210089
Diabetic Foot Ulcer
Diabetes Mellitus
Foot Ulcer
+5 more
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this study is to evaluate prospectively the effect of a novel application of Closed Incision Negative Pressure Wound Therapy (CiNPWT), as delivered by the V.A.C. Ulta™ Therapy System (3M, USA) in individuals who have undergone a Lower Extremity Amputation (LEA) compared with standard of care compression wrapping and wound care post-LEA.
Specific objectives:
1. Collect demographics and relevant data (e.g., risk factors and comorbidities) to compare intervention and control groups.
2. Measure post-surgical outcomes and compare both groups.
STUDY DESIGN
This a pilot-controlled exploratory trial including approximately 6-10 individuals who have undergone LEA (trans-metatarsal or higher) randomized between intervention (novel application of CiNPWT) and a control group (standard care).
DEVICE INFORMATION
The V.A.C. Ulta™ Therapy System (3M, USA) is a non-invasive wound closure system that uses controlled, localized negative pressure to promote healing in chronic and acute wounds. The subatmospheric (ie. negative) pressure system uses latex-free and sterile polyurethane or polyvinyl alcohol foam dressings that are individualized at the bedside to the appropriate size for every patient, and then covered with an adhesive drape to create an airtight seal. A SensaT.R.A.C.™ Pad directly contacts the foam dressing, and accurately senses, monitors, and maintains the target pressure at the wound site to provide controlled negative pressure. Tubing attached to the SensaT.R.A.C.™ Pad connects to a fluid collection canister contained in a programmable, portable, computer-controlled vacuum pump creating negative pressure at the wound surface interface.
Amputation (and revision/re-amputation) is a resection of a segment of a limb through a bone or through a joint.
Major amputation: Any resection proximal to the ankle.
Major amputation levels:
TT = transtibial amputation: amputation through the tibia and fibula (frequently referred to as "below knee amputation").
KD = knee disarticulation: amputation through the knee (frequently referred to as "through knee amputation").
TF = transfemoral amputation: amputation through the femur (frequently referred to as "above knee amputation").
Minor amputation: Any resection distal to the ankle.
Minor amputation levels:
TMA= transmetartarsal amputation.
The level will be determined using the electronic medical record of the patients and by the health care providers observations.
Wound dehiscence (partial or total) is a surgery complication where the incision reopens. Clinically reported by the health care providers. This will be also evaluated with digital photographs.
Infection at the surgical site and/or cellulitis of the residual limb are pathological states caused by invasion and multiplication of microorganisms in host tissues accompanied by tissue destruction and/or a host inflammatory response. This is usually based on soft tissue infection clinical criteria from Infectious Disease Society of America (IDSA) and will be reported by the health care provider.
Closed wound, defined as complete epithelialization at the surgical site, will be based on the health provider's clinical decision combined with medical record documentation. Determination is based on data from wound assessments and photographs performed by the treating clinician and documented in the Tissue Analytics wound imaging software. Photographs will be taken during patient visits (no more than 3x/wk) and if present, wound size, and tissue color percentages will be calculated by Tissue Analytics software. Any wound depth present will be measured manually by the treating therapist and entered into the Tissue Analytics system. Additional wound assessment characteristics that will be documented include periwound color and condition, drainage type or amount, and tissue type assessment. Agreement between clinician's documentation of closure and photographic measurements will be used to ascertain time to closure.
The tolerability/acceptability of CiNPWT will be measured:
* Pain which is a physical suffering or discomfort caused by CiNPWT is usually reported by the patient using the visual analogue scale at each visit.
* Anxiety about the treatment using Hamilton Anxiety Rating Scale (HAM-A)
* Quality of life using the Short Form-36 Questionaire
Baseline characteristics, risk factors and comorbidities will be extracted from the electronic medical record and validated with physical examination. Investigations can be done as necessary to complete missing data such as presence/absence of neuropathy, vascular status, etc., using best practice at the initial evaluation. As an example, blood samples will be obtained at the first evaluation to assess Hemoglobin A1c. If a patient is deemed at nutrition risk based on a nutrition screen done by nursing (Malnutrition Screening Tool), a dietitian will be consulted, and dietary supplementation will be initiated as needed.
All unscheduled or emergency visits will be listed.
At each encounter, the time to complete the treatment including dressings and compression (intervention and control) will be recorded by the clinician in the Electronic Medical Record.
Specific objectives:
1. Collect demographics and relevant data (e.g., risk factors and comorbidities) to compare intervention and control groups.
2. Measure post-surgical outcomes and compare both groups.
STUDY DESIGN
This a pilot-controlled exploratory trial including approximately 6-10 individuals who have undergone LEA (trans-metatarsal or higher) randomized between intervention (novel application of CiNPWT) and a control group (standard care).
DEVICE INFORMATION
The V.A.C. Ulta™ Therapy System (3M, USA) is a non-invasive wound closure system that uses controlled, localized negative pressure to promote healing in chronic and acute wounds. The subatmospheric (ie. negative) pressure system uses latex-free and sterile polyurethane or polyvinyl alcohol foam dressings that are individualized at the bedside to the appropriate size for every patient, and then covered with an adhesive drape to create an airtight seal. A SensaT.R.A.C.™ Pad directly contacts the foam dressing, and accurately senses, monitors, and maintains the target pressure at the wound site to provide controlled negative pressure. Tubing attached to the SensaT.R.A.C.™ Pad connects to a fluid collection canister contained in a programmable, portable, computer-controlled vacuum pump creating negative pressure at the wound surface interface.
Amputation (and revision/re-amputation) is a resection of a segment of a limb through a bone or through a joint.
Major amputation: Any resection proximal to the ankle.
Major amputation levels:
TT = transtibial amputation: amputation through the tibia and fibula (frequently referred to as "below knee amputation").
KD = knee disarticulation: amputation through the knee (frequently referred to as "through knee amputation").
TF = transfemoral amputation: amputation through the femur (frequently referred to as "above knee amputation").
Minor amputation: Any resection distal to the ankle.
Minor amputation levels:
TMA= transmetartarsal amputation.
The level will be determined using the electronic medical record of the patients and by the health care providers observations.
Wound dehiscence (partial or total) is a surgery complication where the incision reopens. Clinically reported by the health care providers. This will be also evaluated with digital photographs.
Infection at the surgical site and/or cellulitis of the residual limb are pathological states caused by invasion and multiplication of microorganisms in host tissues accompanied by tissue destruction and/or a host inflammatory response. This is usually based on soft tissue infection clinical criteria from Infectious Disease Society of America (IDSA) and will be reported by the health care provider.
Closed wound, defined as complete epithelialization at the surgical site, will be based on the health provider's clinical decision combined with medical record documentation. Determination is based on data from wound assessments and photographs performed by the treating clinician and documented in the Tissue Analytics wound imaging software. Photographs will be taken during patient visits (no more than 3x/wk) and if present, wound size, and tissue color percentages will be calculated by Tissue Analytics software. Any wound depth present will be measured manually by the treating therapist and entered into the Tissue Analytics system. Additional wound assessment characteristics that will be documented include periwound color and condition, drainage type or amount, and tissue type assessment. Agreement between clinician's documentation of closure and photographic measurements will be used to ascertain time to closure.
The tolerability/acceptability of CiNPWT will be measured:
* Pain which is a physical suffering or discomfort caused by CiNPWT is usually reported by the patient using the visual analogue scale at each visit.
* Anxiety about the treatment using Hamilton Anxiety Rating Scale (HAM-A)
* Quality of life using the Short Form-36 Questionaire
Baseline characteristics, risk factors and comorbidities will be extracted from the electronic medical record and validated with physical examination. Investigations can be done as necessary to complete missing data such as presence/absence of neuropathy, vascular status, etc., using best practice at the initial evaluation. As an example, blood samples will be obtained at the first evaluation to assess Hemoglobin A1c. If a patient is deemed at nutrition risk based on a nutrition screen done by nursing (Malnutrition Screening Tool), a dietitian will be consulted, and dietary supplementation will be initiated as needed.
All unscheduled or emergency visits will be listed.
At each encounter, the time to complete the treatment including dressings and compression (intervention and control) will be recorded by the clinician in the Electronic Medical Record.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Wound Heal
Wound Dehiscence
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Intervention
Following amputation, at POD 1, CiNPWT will be applied in an "envelope-like" fashion, incorporating the incison line as well as \~10 cm of intact proximal residual limb tissue. The underlying skin will be protected with a contact layer and the negative pressure foam is applied for maximal surface area coverage. Negative pressure parameters are set to dynamic pressure control therapy (DPC) from -25 mmHg to -125 mmHg with a 2 minute on/2 minute off cycle and the dressing is left in place for three to five days.
A patient may always be removed from treatment intervention whenever they wish.
Control
Following amputation, at POD 1, application of standard care (short stretch compression bandages and standard post-operative wound care) daily.
Following amputation, at POD 1, CiNPWT will be applied in an "envelope-like" fashion, incorporating the incison line as well as \~10 cm of intact proximal residual limb tissue. The underlying skin will be protected with a contact layer and the negative pressure foam is applied for maximal surface area coverage. Negative pressure parameters are set to dynamic pressure control therapy (DPC) from -25 mmHg to -125 mmHg with a 2 minute on/2 minute off cycle and the dressing is left in place for three to five days.
A patient may always be removed from treatment intervention whenever they wish.
Control
Following amputation, at POD 1, application of standard care (short stretch compression bandages and standard post-operative wound care) daily.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group: Standard of Care
Following amputation, at POD 1, application of standard care (short stretch compression bandages and standard post-operative wound care) daily.
Group Type
ACTIVE_COMPARATOR
Standard of Care group
Intervention Type
PROCEDURE
The control group will receive standard of care wound treatment
CiNPWT treatment group
Following amputation, at POD 1, CiNPWT will be applied in an "envelope-like" fashion, incorporating the incison line as well as \~10 cm of intact proximal residual limb tissue. The underlying skin will be protected with a contact layer and the negative pressure foam is applied for maximal surface area coverage. Negative pressure parameters are set to dynamic pressure control therapy (DPC) from -25 mmHg to -125 mmHg with a 2 minute on/2 minute off cycle and the dressing is left in place for three to five days.
A patient may always be removed from treatment intervention whenever they wish.
Group Type
EXPERIMENTAL
CINPWT
Intervention Type
DEVICE
Subject will receive CINPWT until discharged
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard of Care group
The control group will receive standard of care wound treatment
Intervention Type
PROCEDURE
CINPWT
Subject will receive CINPWT until discharged
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individual aged 18 years or older
* Individual with a closed incision following LEA (transmetatarsal or proximal)
* Individual presents with adequate perfusion based on WIfI ischemia component score of less than 2 (\>30mm Hg TCPO2 or higher at region of amputation)
* Individual presents with no residual surgical site infection (WIfI grade 0) post LEA
* Individual is competent to make their own medical decisions
* Individual with a closed incision following LEA (transmetatarsal or proximal)
* Individual presents with adequate perfusion based on WIfI ischemia component score of less than 2 (\>30mm Hg TCPO2 or higher at region of amputation)
* Individual presents with no residual surgical site infection (WIfI grade 0) post LEA
* Individual is competent to make their own medical decisions
Exclusion Criteria
* Individual presents with any defined contraindications to NPWT (e.g., allergy).
* Individual presents with residual acute osteomyelitis (after amputation).
* Individual with collagen vascular disease or malignant disease in the wound
* Individual has uncontrolled hyperglycemia (glycosylated hemoglobin \[HbA1c\]\>12%).
* Individual is currently taking corticosteroids, immunosuppressive drugs, or chemotherapy and is not on stable course of therapy as determined by principal investigator
* Individual has a history of local radiation therapy that could impact the edema of the amputated limb.
* Individual has pre-existing conditions contributing to residual limb edema (i.e., nephropathy, congestive heart failure, primary lymphedema, etc.).
Withdrawal of individuals:
* Voluntary withdrawal
* Death
* Lost to follow-up
* Termination of compression therapy (control or intervention group)
* Individual presents with residual acute osteomyelitis (after amputation).
* Individual with collagen vascular disease or malignant disease in the wound
* Individual has uncontrolled hyperglycemia (glycosylated hemoglobin \[HbA1c\]\>12%).
* Individual is currently taking corticosteroids, immunosuppressive drugs, or chemotherapy and is not on stable course of therapy as determined by principal investigator
* Individual has a history of local radiation therapy that could impact the edema of the amputated limb.
* Individual has pre-existing conditions contributing to residual limb edema (i.e., nephropathy, congestive heart failure, primary lymphedema, etc.).
Withdrawal of individuals:
* Voluntary withdrawal
* Death
* Lost to follow-up
* Termination of compression therapy (control or intervention group)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southern California
OTHER
Sponsor Role
lead
3M
INDUSTRY
Sponsor Role
collaborator
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Armstrong
Dr. David Armstrong DPM, MD, PhD, Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
References
Explore related publications, articles, or registry entries linked to this study.
Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983 May;16(1):87-101. doi: 10.1016/0304-3959(83)90088-X.
Reference Type
BACKGROUND
Upton D, Stephens D, Andrews A. Patients' experiences of negative pressure wound therapy for the treatment of wounds: a review. J Wound Care. 2013 Jan;22(1):34-9. doi: 10.12968/jowc.2013.22.1.34.
Reference Type
BACKGROUND
Fortington LV, Geertzen JH, van Netten JJ, Postema K, Rommers GM, Dijkstra PU. Short and long term mortality rates after a lower limb amputation. Eur J Vasc Endovasc Surg. 2013 Jul;46(1):124-31. doi: 10.1016/j.ejvs.2013.03.024. Epub 2013 Apr 28.
Reference Type
BACKGROUND
Low EE, Inkellis E, Morshed S. Complications and revision amputation following trauma-related lower limb loss. Injury. 2017 Feb;48(2):364-370. doi: 10.1016/j.injury.2016.11.019. Epub 2016 Nov 18.
Reference Type
BACKGROUND
Morisaki K, Yamaoka T, Iwasa K. Risk factors for wound complications and 30-day mortality after major lower limb amputations in patients with peripheral arterial disease. Vascular. 2018 Feb;26(1):12-17. doi: 10.1177/1708538117714197. Epub 2017 Jun 6.
Reference Type
BACKGROUND
Goldberg T. Postoperative management of lower extremity amputations. Phys Med Rehabil Clin N Am. 2006 Feb;17(1):173-80, vii. doi: 10.1016/j.pmr.2005.10.009.
Reference Type
BACKGROUND
Ahuja V, Thapa D, Ghai B. Strategies for prevention of lower limb post-amputation pain: A clinical narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):439-449. doi: 10.4103/joacp.JOACP_126_17.
Reference Type
BACKGROUND
Nawijn SE, van der Linde H, Emmelot CH, Hofstad CJ. Stump management after trans-tibial amputation: a systematic review. Prosthet Orthot Int. 2005 Apr;29(1):13-26. doi: 10.1080/17461550500066832.
Reference Type
BACKGROUND
Hyldig N, Birke-Sorensen H, Kruse M, Vinter C, Joergensen JS, Sorensen JA, Mogensen O, Lamont RF, Bille C. Meta-analysis of negative-pressure wound therapy for closed surgical incisions. Br J Surg. 2016 Apr;103(5):477-86. doi: 10.1002/bjs.10084.
Reference Type
BACKGROUND
Scalise A, Calamita R, Tartaglione C, Pierangeli M, Bolletta E, Gioacchini M, Gesuita R, Di Benedetto G. Improving wound healing and preventing surgical site complications of closed surgical incisions: a possible role of Incisional Negative Pressure Wound Therapy. A systematic review of the literature. Int Wound J. 2016 Dec;13(6):1260-1281. doi: 10.1111/iwj.12492. Epub 2015 Oct 1.
Reference Type
BACKGROUND
Strugala V, Martin R. Meta-Analysis of Comparative Trials Evaluating a Prophylactic Single-Use Negative Pressure Wound Therapy System for the Prevention of Surgical Site Complications. Surg Infect (Larchmt). 2017 Oct;18(7):810-819. doi: 10.1089/sur.2017.156. Epub 2017 Sep 8.
Reference Type
BACKGROUND
Armstrong DG, Lavery LA; Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet. 2005 Nov 12;366(9498):1704-10. doi: 10.1016/S0140-6736(05)67695-7.
Reference Type
BACKGROUND
Sanders JE, Fatone S. Residual limb volume change: systematic review of measurement and management. J Rehabil Res Dev. 2011;48(8):949-86. doi: 10.1682/jrrd.2010.09.0189.
Reference Type
BACKGROUND
Zwanenburg PR, Timmermans FW, Timmer AS, Middelkoop E, Tol BT, Lapid O, Obdeijn MC, Gans SL, Boermeester MA. A systematic review evaluating the influence of incisional Negative Pressure Wound Therapy on scarring. Wound Repair Regen. 2021 Jan;29(1):8-19. doi: 10.1111/wrr.12858. Epub 2020 Aug 21.
Reference Type
BACKGROUND
West J, Wetherhold J, Schulz S, Valerio I. A Novel Use of Next-Generation Closed Incision Negative Pressure Wound Therapy After Major Limb Amputation and Amputation Revision. Cureus. 2020 Sep 11;12(9):e10393. doi: 10.7759/cureus.10393.
Reference Type
BACKGROUND
Kilpadi DV, Olivie M. Evaluation of closed incision negative pressure therapy systems on the closure of incisional space model. J Wound Care. 2019 Dec 2;28(12):850-860. doi: 10.12968/jowc.2019.28.12.850.
Reference Type
BACKGROUND
Singh D, Livingstone JP, Lautze J, Murray PC. Measuring In-Vivo Foot Perfusion Distal to a Near-Circumferential Negative Pressure Wound Therapy Dressing via Thermal Imaging. Cureus. 2021 Sep 4;13(9):e17720. doi: 10.7759/cureus.17720. eCollection 2021 Sep.
Reference Type
BACKGROUND
Rafter N, Hickey A, Condell S, Conroy R, O'Connor P, Vaughan D, Williams D. Adverse events in healthcare: learning from mistakes. QJM. 2015 Apr;108(4):273-7. doi: 10.1093/qjmed/hcu145. Epub 2014 Jul 29.
Reference Type
BACKGROUND
van Netten JJ, Bus SA, Apelqvist J, Lipsky BA, Hinchliffe RJ, Game F, Rayman G, Lazzarini PA, Forsythe RO, Peters EJG, Senneville E, Vas P, Monteiro-Soares M, Schaper NC; International Working Group on the Diabetic Foot. Definitions and criteria for diabetic foot disease. Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3268. doi: 10.1002/dmrr.3268. Epub 2020 Jan 14.
Reference Type
BACKGROUND
Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346.
Reference Type
BACKGROUND
Stouka X, Stergiannis P, Konstantinou E, Katsoulas T, Intas G, Skopa R, Fildissis G. Health-Related Quality of Life and Rehabilitation Costs of Patients with Amputated Limb. Adv Exp Med Biol. 2021;1337:237-243. doi: 10.1007/978-3-030-78771-4_27.
Reference Type
BACKGROUND
Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Med Res Methodol. 2013 Aug 20;13:104. doi: 10.1186/1471-2288-13-104.
Reference Type
BACKGROUND
Creager MA, Matsushita K, Arya S, Beckman JA, Duval S, Goodney PP, Gutierrez JAT, Kaufman JA, Joynt Maddox KE, Pollak AW, Pradhan AD, Whitsel LP. Reducing Nontraumatic Lower-Extremity Amputations by 20% by 2030: Time to Get to Our Feet: A Policy Statement From the American Heart Association. Circulation. 2021 Apr 27;143(17):e875-e891. doi: 10.1161/CIR.0000000000000967. Epub 2021 Mar 25.
Reference Type
RESULT
Molina CS, Faulk J. Lower Extremity Amputation. 2022 Aug 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK546594/
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APP-22-00260 USC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
External Shoe Lift to Improve Healing and Adherence in Patients With Diabetic Foot Ulcers
NCT04117269
UNKNOWN
NA
Study to Assess the Efficacy of Direct Observation and Mental Visualization of Foot Movements to Treat Bilateral Lower Limb Phantom Limb Pain
NCT00639431
UNKNOWN
NA
Polyurethane Foam on the Heel for Prevention in Children
NCT03039179
COMPLETED
NA
Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer
NCT01844479
COMPLETED
NA
Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers
NCT02533726
COMPLETED
NA
Effects of Shrinker Use on Healing and Volume
NCT00693628
TERMINATED
NA
Wound Healing: Total Contact Cast Vs. Custom-Made Temporary Footwear for Patients With Diabetic Foot Ulceration
NCT00304733
UNKNOWN
NA
Insole Optimisation for Ulcer Prevention: a Feasibility Trial
NCT01948479
UNKNOWN
NA
Achilles Tendon Lengthening in Patients With Diabetes to Prevent Foot Ulcers
NCT00006426
COMPLETED
PHASE1
Study Evaluating rhMBP-2/CPM in Open Wedge Osteotomies
NCT00243295
COMPLETED
PHASE1
Use of Perforator Flaps for Leg and Foot Reconstruction
NCT03269864
UNKNOWN
NA
Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites
NCT01645722
COMPLETED
NA
Drug Delivery Devices for Osteomyelitis
NCT02968693
COMPLETED
Vacuum Suspension: Effects on Tissue Oxygenation, Activity and Fit
NCT00117793
COMPLETED
NA
Bioimpedance as a Diagnostic Tool for Assessing the Need for Socket Modification in Transtibial Amputees
NCT03164356
COMPLETED
NA
The Effect of Implementing a Limb Loss Prevention Program on Amputation Rates
NCT03978715
COMPLETED
Sural Flap and Anterolateral Thigh Flap in Tissue Reconstruction Around the Ankle
NCT04906967
UNKNOWN
NA
Clinical Trial of Footwear in Patients With Diabetes
NCT00032864
COMPLETED
Effects of Windlass Versus Calcaneal Taping in Football Player With Plantar Fasciitis.
NCT06637592
RECRUITING
NA
Maximal Plantar Pressure and Comfort Evaluation of Orthopedic Stilettos
NCT02667990
COMPLETED
NA
Contribution of Near-InfraRed Spectroscopy (NIRS) to the Evaluation of Healing After Amputation of the Leg
NCT02551484
TERMINATED
NA
Incidence and Factors Affecting the Development and Outcome of Phantom Limb Pain (PLP) - A Single-centre Prospective Cohort Study.
NCT05005481
UNKNOWN
Efficacy of Negative Pressure Wound Therapy After Total Ankle Arthroplasty
NCT03886818
COMPLETED
NA
Functional Ankle Taping Correction on Plantar Foot Ulcer Healing in Diabetic Patients
NCT06065488
COMPLETED
NA
Prosthetic Limbs After Leg Amputation: Alternative Method of Socket Design
NCT00061217
UNKNOWN
PHASE2